astrazeneca plc-spons adr (AZN) Key Developments
AstraZeneca PLC Presents at Australia Biotech Invest 2015, Oct-07-2015 09:30 AM
Oct 6 15
AstraZeneca PLC Presents at Australia Biotech Invest 2015, Oct-07-2015 09:30 AM. Venue: Crown Conference Centre, Crown Promenade Hotel, Melbourne, Victoria, Australia. Speakers: Ajay Gautam, Executive Director, IMED Scientific Partnering & Alliances.
AstraZeneca Announces Availability of New Dose of Brilinta in US Pharmacies
Sep 29 15
AstraZeneca announced that BRILINTA® (ticagrelor) 60-mg tablets are now available in US pharmacies. On September 3, 2015, the US Food and Drug Administration (FDA) approved a new 60-mg dosage strength for BRILINTA to be used in patients with a history of heart attack beyond the first year. BRILINTA is approved to reduce the rate of cardiovascular (CV) death, myocardial infarction ([MI], also known as heart attack) and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, BRILINTA is superior to clopidogrel. BRILINTA is the first and only FDA approved oral antiplatelet to demonstrate superior reductions in CV death versus clopidogrel at 12 months. The dosing of BRILINTA in the management of ACS is 90 mg twice daily during the first year after an ACS event. After one year, patients with a history of heart attack can now be treated with 60 mg twice daily. BRILINTA must be used with a daily maintenance dose of aspirin of 75-100mg. AstraZeneca is committed to supporting patient access to BRILINTA and connecting patients with the information and support they need. For patients who have been prescribed BRILINTA, AstraZeneca offers the BRILINTA Patient Support Service (BPSS) tool that provides resources and support to help patients and caregivers from hospital discharge throughout the ACS treatment journey. To help loved ones, the program offers important patient education and coaching in addition to savings offers, refill reminders, personal pharmacy locator, co-pay calculator, and coverage verification and information.
AstraZeneca PLC Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 03:40 PM
Sep 25 15
AstraZeneca PLC Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 03:40 PM. Venue: Le Parker Meridien Hotel, New York, New York, United States. Speakers: Robert Iannone, SVP, Head of Immuno-oncology, Global Medicines Development.
HHS to Collaborate with Astrazeneca for Biodefense Preparedness Plan
Sep 24 15
HHS will collaborate with AstraZeneca on an antibiotic initiative as part of a biodefense preparedness plan for dealing with public health threats. The public-private partnership will bring together for the second time the Biomedical Advanced Research and Development Authority wing of the HHS with a drug company to develop investigational medications that could potentially be used to ward off bioterrorism and deadly bacterial infections or pandemics. With $50 million in up-front BARDA funding and up to $170 million down the road, depending on the products, the agreement is a turn toward investing in a roster of drugs, rather than single products to speed up the process and create more options. HHS and AZ have eyed ATM-AVI (Aztreonam and Avibactam) to study its use against meliodosis, glanders and the plague.
AstraZeneca PLC Presents at BioPharm America 2015, Sep-15-2015 09:40 AM
Sep 12 15
AstraZeneca PLC Presents at BioPharm America 2015, Sep-15-2015 09:40 AM. Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.